zebit0 April 15, 2026, 4:45am #8 Assuming someone does not have Wilsons disease or is even a carrier for it, in which case the remarkably high dose would be significantly lower (for carriers) or lethal (for those with Wilsons)
In fact, I suspect we are still in the earliest stages of what may ultimately become one of the largest shifts in metabolic medicine in decades
#TaibaRare #RareMetabolicDisease #PatientAwareness #LipodystrophyAwareness #RareDisease #MetabolicHealth #WorldLipodystrophyDay #RareDisorders #ChronicIllness To view or add a comment, sign in Ashley Shoemaker, MD, MSci, of Vanderbilt Health discusses the FDA approval of setmelanotide (Imcivree), the first targeted therapy for acquired hypothalamic obesity in patients 4+ years
Dark Knees, Elbows, or Underarms
The FDA has documented cases where patients experienced symptoms lasting several days after accidental overdoses
Psychiatry 66, 185190